Alyssum Therapeutics
Latest round
- Series A
Last raised
- Jan 2025
Total raised
- $11M
Investors
- 4
About Alyssum Therapeutics
Alyssum Therapeutics Inc is engaged in the development of immunotherapy treatments that modulate B cells for complex diseases.00 mn.Alyssum Therapeutics specializes in innovative immunotherapy solutions focused on modulating B cells to address complex diseases, particularly cancers and autoimmune disorders. The company's lead candidate, AT1965, is a small molecule currently in Phase 1 clinical trials for advanced solid malignancies. AT1965 targets CMTR2 in cancer cells to stimulate a B cell immune response, showing promise in regressing hard-to-treat solid tumors and enhancing the efficacy of immune checkpoint inhibitors. The modulation of B cells aims to improve patient outcomes in various solid tumors, including breast cancer, melanoma, and cervical cancer.Alyssum Therapeutics generates revenue through partnerships and collaborations in the biopharmaceutical sector, focusing on the development of its flagship product, AT1965. The company engages in B2B transactions with pharmaceutical companies and research institutions, facilitating licensing agreements and joint development initiatives. Revenue is derived from milestones achieved throughout the clinical trial phases, potential royalties on future product sales, and upfront payments from strategic partnerships. The pricing structure for their therapies is determined upon successful completion of clinical trials and subsequent commercialization agreements, aligning with industry standards for similar biopharmaceutical products. Future initiatives include the design and launch of new products aimed at addressing additional disease areas within oncology and autoimmune disorders. Additionally, the company plans to expand its operational reach into new markets in Europe by 2026 and the Asia-Pacific region by 2027.
Who invested in Alyssum Therapeutics
4 investors across 2 rounds
See all investors in Alyssum Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alyssum Therapeutics
Who invested in Alyssum Therapeutics?
Alyssum Therapeutics has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alyssum Therapeutics raised?
Alyssum Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Alyssum Therapeutics last raise money?
Alyssum Therapeutics's most recent round on record is a Series A, in Jan 2025.
What does Alyssum Therapeutics do?
Alyssum Therapeutics Inc is engaged in the development of immunotherapy treatments that modulate B cells for complex diseases.
Where is Alyssum Therapeutics headquartered?
Alyssum Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Alyssum Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Alyssum Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Alyssum Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.